ADAs to Alemtuzumab

Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis

NCT03983252 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

NCT03368664 ·Status: TERMINATED ·Phase: PHASE3

Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment

NCT03806387 ·Status: COMPLETED

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

NCT03073603 ·Status: COMPLETED ·Phase: PHASE4

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

NCT03135249 ·Status: COMPLETED ·Phase: PHASE4

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis

NCT01767701 ·Status: COMPLETED ·Phase: PHASE2

ATX-MS-1467 in Multiple Sclerosis

NCT01973491 ·Status: COMPLETED ·Phase: PHASE2

Advanced MRI Measures of Repair in Alemtuzumab Treated Patients

NCT01307332 ·Status: COMPLETED ·Phase: PHASE3

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential

NCT02419378 ·Status: COMPLETED ·Phase: PHASE4

The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients

NCT03193086 ·Status: UNKNOWN

COMparison Between All immunoTherapies for Multiple Sclerosis.

NCT03193866 ·Status: COMPLETED

Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis

NCT03113162 ·Status: UNKNOWN ·Phase: PHASE1

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

NCT05834855 ·Status: RECRUITING ·Phase: PHASE3

Towards Personalized Dosing of Natalizumab in Multiple Sclerosis

NCT03516526 ·Status: COMPLETED ·Phase: PHASE4

Advanced MRI Sequences in Multiple Sclerosis and Its Mimics

NCT03608605 ·Status: UNKNOWN

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

NCT03737851 ·Status: COMPLETED ·Phase: PHASE2

Short-term B-cell Depletion in Relapsing Multiple Sclerosis

NCT03853746 ·Status: COMPLETED ·Phase: PHASE4

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

NCT05418010 ·Status: RECRUITING ·Phase: PHASE2

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

NCT00035529 ·Status: TERMINATED ·Phase: PHASE2

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

NCT05296161 ·Status: RECRUITING ·Phase: PHASE4

Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients

NCT03315923 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

NCT03085810 ·Status: TERMINATED ·Phase: PHASE3

Neurofilaments for NEDA Assessing in MS

NCT03250169 ·Status: TERMINATED

Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis

NCT03996291 ·Status: COMPLETED ·Phase: PHASE2

Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS

NCT04838015 ·Status: UNKNOWN